Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

NCT02273362 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Cirrhosis
Hepatocellular Carcinoma

Interventions

DRUG: Erlotinib
DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment

Sponsor

National Cancer Institute (NCI)